InventisBio Announces Positive Phase 2 Study Results for D-2570 (TYK2 Inhibitor) in Patients with Moderate to Severe Plaque Psoriasis 12/03/2024
Officially Approved. Anfangning (KRAS G12C Inhibitor Garsorasib) Receives Market Authorization from the National Medical Products Administration (NMPA) of China 11/11/2024
2024 WCLC | Latest Progress of Garsorasib (D-1553) in Treating KRAS G12C-Mutant Lung Cancer: Phase 2 Study Updates 09/10/2024
Garsorasib (D-1553) Phase II Study Results for Lung Cancer Published in Prestigious International Journal 06/11/2024
InventisBio to Present Phase II Clinical Data of Garsorasib (D-1553) for Lung Cancer at the 2024 AACR Annual Meeting 03/13/2024
